{"DataElement":{"publicId":"2597545","version":"2","preferredName":"Cytochrome Enzyme Name","preferredDefinition":"Specific name of the CYP enzyme for which activity is being measured.","longName":"CYTCHR_ENYM_NM","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"2405041","version":"1","preferredName":"Hormone Therapy Anastrozole Received","preferredDefinition":"Information related to patient/participant having received anastrozole, a hormone therapy, which selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","longName":"HORMTX_ANA_RCVD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2433915","version":"1","preferredName":"Hormone Therapy","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA8-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2743990","version":"1","preferredName":"Anastrozole Received","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04):Received; taken, gotten, or acquired.","longName":"C1607:C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B78CA2F-38C6-68D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-22","modifiedBy":"ONEDATA","dateModified":"2008-04-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0EE7-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-09-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2597539","version":"2","preferredName":"Cytochrome Enzyme Name","preferredDefinition":"The name of the protein that speeds up chemical reactions in the body.","longName":"CYT_ENYM_NM","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CYP2C9","valueDescription":"CYP2C9","ValueMeaning":{"publicId":"2597540","version":"1","preferredName":"CYP2C9","longName":"2597540","preferredDefinition":"CYP2C9","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2998C402-3FCD-4667-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AEBDFFC-B5B1-BA03-E040-BB89AD437F64","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-01-28","modifiedBy":"ONEDATA","dateModified":"2011-01-28","deletedIndicator":"No"},{"value":"CYP3A4","valueDescription":"CYP3A4","ValueMeaning":{"publicId":"2597542","version":"1","preferredName":"CYP3A4","longName":"2597542","preferredDefinition":"CYP3A4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2998C433-8348-466B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AEBDFFC-B5C5-BA03-E040-BB89AD437F64","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-01-28","modifiedBy":"ONEDATA","dateModified":"2011-01-28","deletedIndicator":"No"},{"value":"CYP1A2","valueDescription":"CYP1A2","ValueMeaning":{"publicId":"2597543","version":"1","preferredName":"CYP1A2","longName":"2597543","preferredDefinition":"CYP1A2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2998C43A-6E80-466E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AEBDFFC-B5CF-BA03-E040-BB89AD437F64","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-01-28","modifiedBy":"ONEDATA","dateModified":"2011-01-28","deletedIndicator":"No"},{"value":"CYP2D6 polymorphism","valueDescription":"CYP2D6 polymorphism","ValueMeaning":{"publicId":"2825086","version":"1","preferredName":"CYP2D6 polymorphism","longName":"2825086","preferredDefinition":"CYP2D6 polymorphism","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6086BC01-99A3-FFDF-E040-BB89AD436742","latestVersionIndicator":"Yes","beginDate":"2009-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-01-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AEBDFFC-B5EE-BA03-E040-BB89AD437F64","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-01-28","modifiedBy":"ONEDATA","dateModified":"2011-01-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2182370","version":"1","preferredName":"Procedures","preferredDefinition":"Tests, examinations, evaluations used to determine a subject's status or response to intervention.  ","longName":"PROCEDURES","context":"CCR","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7049CF8-1252-211C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-01","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-01","modifiedBy":"REEVESD","dateModified":"2004-09-24","changeDescription":"Created initially to support CCR value domain for CTMS. ","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2597538","version":"1","preferredName":"Cytochrome Enzyme Name","preferredDefinition":"Hemeproteins whose characteristic mode of action involves transfer of reducing equivalents associated with a reversible change in oxidation state of the prosthetic group. Formally, this redox change involves a single-electron, reversible equilibrium between the Fe(II) and Fe(III) states of the central iron atom. (From Enzyme Nomenclature, 1992, p539):A protein that speeds up chemical reactions in the body.:The words or language units by which a thing is known.","longName":"C16486:C16554:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytochrome","conceptCode":"C16486","definition":"A family of membrane-associated, heme-containing proteins that catalyze oxidation and reduction to promote electron transport reactions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Enzyme","conceptCode":"C16554","definition":"Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2998C302-4E3F-44B8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-02-16","modifiedBy":"ONEDATA","dateModified":"2007-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AEBDFFC-B59B-BA03-E040-BB89AD437F64","latestVersionIndicator":"Yes","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-01-28","modifiedBy":"MAESKEB","dateModified":"2011-01-28","changeDescription":"Increased length to accomodate values.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2194255","version":"1","longName":"Type of Condition","context":"DCP","ClassificationSchemeItems":[{"publicId":"2812736","version":"1","longName":"Transdermal 4-OHT vs oral TAM DCIS of the Breast","context":"DCP"},{"publicId":"2812258","version":"1","longName":"Drug and Carcinogen Enzymes - Resveratrol","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Enzyme Activity","type":"Preferred Question Text","description":"Enzyme Activity","url":null,"context":"DCP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AEBDFFC-B606-BA03-E040-BB89AD437F64","latestVersionIndicator":"Yes","beginDate":"2007-02-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-01-28","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}